CD45+ immune cells infiltrating 99LN‐BrM (n = 5 for isotype, n = 4 for the other groups).
Flow cytometric analysis of dendritic cell (CD45+CD11c+CD83+) infiltration (n = 4 for isotype, n = 3 for all other groups).
Quantitative analysis of IHC CD3+ T cells at trial end point (n = 10 for isotype, n = 7 for WBRT, n = 10 for αPD‐1, and n = 8 for WBRT + αPD‐1 group).
Flow cytometric analysis of T‐cell subpopulations in 99LN‐BrM (n = 4 for isotype, n = 3 for all other groups).
Quantitative analysis of IHC FoxP3+ T cells at trial end point (n = 10 for isotype, n = 7 for WBRT, n = 10 for αPD‐1, and n = 8 for WBRT + αPD‐1 group).
Flow cytometric analysis of PD‐1 expression on T cells in response to different treatments (control n = 4, all other groups n = 3).
Composition of the myeloid compartment in 99LN‐BrM in the different treatment groups (n = 5 for isotype, all other groups n = 4).
Relative abundance (%) of PD‐L1+ myeloid cell types in BrM samples of the four treatment groups (n = 5 for isotype, all other groups n = 4).
Experimental design of the in vitro T‐cell activation assay.
Relative CD69 protein level on T cells cultivated with different cell types, unstimulated, or stimulated with tumor‐conditioned media (Cond.) (n = 3).
Relative Gzmb and IFNγ protein level on CD4+ and CD8+ T cells cultivated with different cell types, with or without αPD‐1 and unstimulated or stimulated with tumor‐conditioned media (Cond.) (n = 4 for conditions including BMDM, n = 5 for all other conditions).